It is indeed our pleasure to have Prof Sir David Lane and Prof Jack A Gilbert as our plenary speakers for NCAM 2017!
Registration is now Closed!
We wish to thank you for your participation at the 4th NCIS Annual Research Meeting (NCAM 2017).
Abstract submission Closed!
Thank you for the submissions.
Healthcare through research
Dear friends and colleagues,
On behalf of the organizing committee, we warmly welcome you to join the 4th NCIS Annual Research Meeting (NCAM) 2017, to be held on 30 June to 1 July 2017. NCAM 2016 was successfully held on 1st July 2016, and attracted more than 250 registrants and close to 100 scientific abstracts. The meeting created a forum for clinicians and scientists to interact and showcase their cancer research work on the NCIS campus. Our theme this year is on ‘Optimizing Cancer Treatments through Science’. On day 1, we will have a full-day program including educational sessions, oral and poster presentations of submitted abstracts, and award presentation for the best abstracts. We welcome you to submit abstracts on cancer research in the following four categories: basic science, clinical science, translational science, and nursing/paramedical/supportive care. Selected abstracts will be presented on day 1 at the main meeting. In addition, this year’s NCAM will feature a half-day mini-symposium on day 2 that will focus on the latest advances in Gynae-Oncology.
This conference will provide an excellent platform for cancer physicians and researchers in Singapore to interact and develop future collaborations. We look forward to welcoming you to the 4th NCIS Annual Research Meeting (NCAM) 2017.
Soo Chin Lee
Philip H. Koeffler
Mini Symposium 2017
Ovarian cancer is the most lethal gynaecological malignancy. Recent advances in our understanding of the underlying molecular aberrations in ovarian cancer, and in the development of new drugs for ovarian cancer are now providing unique opportunities for precision medicine in the management of this disease. With the approvals of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab for use in front line and recurrent ovarian cancer treatment, and the first poly ADP ribose polymerase (PARP) inhibitor, Olaparib, for use in the treatment of recurrent BRCA1/2 mutant ovarian cancer by the US FDA and EMA, it is almost certain that numerous therapeutic possibilities are yet to be explored.
This Ovarian Cancer Mini-Symposium gathers experts in the field to cover recent scientific research advancements which lead to improved patient management. This is a continuous effort to bring together the collaborative group of ovarian cancer experts following the success of Singapore Ovarian Cancer Symposium held in 2010, 2012, and 2014. In conjunction with NCAM 2017, the Ovarian Cancer Mini-Symposium hopes to provide updated perspectives to a boarder audience within the oncology profession to create more awareness of this deadly disease.
Ruby Yun-Ju Huang
Mini Symposium Chairperson
Senior Resident Physician, NUH
Principal Investigator, CSI Singapore